СИСТЕМНЫЙ ЮВЕНИЛЬНЫЙ ИДИОПАТИЧЕСКИЙ АРТРИТ: МЕХАНИЗМЫ РАЗВИТИЯ, МИШЕНИ ДЛЯ ГЕННО-ИНЖЕНЕРНОЙ БИОЛОГИЧЕСКОЙ ТЕРАПИИ

1. Still G. F. On a form of chronic joint disease in children. Med-Chir. Trans. 1897; 80: 47–59.

2. Schneider R., Laxer R. M. Systemic onset juvenile rheumatoid arthritis. Baillieres Clin Rheumatol. 1998; 12: 245–271.

3. Hadchouel M., Prieur A. M., Griscelli C. Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. J. Pediatr. 1985; 106 (4): 561–566.

4. Ramanan A. V., Schneider R. Macrophage activation syndrome what's in a name! J. Rheumatol. 2003; 30: 2513–2516.

5. Athreya B. H. Is macrophage activation syndrome a new entity? Clin. Exp. Rheumatol. 2002; 20: 121–123.

6. Grom A. A. NK dysfunction: a common pathway in systemic onset juvenile rheumatoid arthritis, macrophage activation syndrome and hemophagocytic lymphohistiocytosis. Arthritis Rheum. 2004; 50: 689–698.

7. Filipovich H. A. Hemophagocytic lymphohistiocytosis. Immunol Allergy Clin. N. Am. 2002; 22: 281–300.

8. Henter J. I., Horne A., Arico M. et al. Diagnostic and therapeutic guidelines for hemopagocytic lymphohistiocytosis. Pediatr. Blood Cancer. 2007; 48: 124–131.

9. Lang B. A. et al. Radiologic features of systemic onset juvenile rheumatoid arthritis. J. Rheumatol. 1995; 22: 168–173.

10. Lomater C., Gerloni V., Gattinara M. et al. Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J. Rheumatol. 2000; 27: 491–496.

11. Ramanan A. V., Grom A. A. Does systemic-onset juvenile idiopathic arthritis belong under juvenile idiopathic arthritis? Rheumatology (Oxford). 2005; 44: 1350–1353.

12. Frosch M., Roth J. New insights in systemic juvenile idiopathic arthritis — from pathophysiology to treatment. Rheumatology (Oxford). 2008; 47: 121–125.

13. Beutler B. Inferences, questions and possibilities in Toll-like receptor signaling. Nature. 2004; 430: 257–263.

14. Hull K. M., Shoham N., Chae J. J. et al. The expanding spectrum of systemic autoinflammtory disorders and their rheumatic manifestations. Curr. Opin. Rheumatol. 2003; 15: 61–69.

15. Pascual V., Allantaz F., Arce E. et al. Role of Interleukin-1 in the pathogenesis of systemic juvenile idiopathic arthritis and clinical response to IL-1 blockde. J. Exp. Med. 2005; 201: 1479–1486.

16. Fall N., Barnes M., Thornton S. et al. Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum. 2007; 56: 3793–3804.

17. Ogilvie E. M., Khan A., Hubank M. et al. Specific gene expression profiles in systemic juvenile idiopathic arthritis. Arthritis Rheum. 2007; 56: 1954–1965.

18. Barnes M. G., Grom A. A., Thompson S. D. et al. Gene Expression Signatures in new onset untreated juvenile idiopathic arthritis. Arthritis Rheum. 2009; 60: 2101–2112.

19. Allantaz F., Chaussabel D., Stichweh D. et al. Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J. Exp. Med. 2007; 204: 2131–2144.

20. Nepom B. G., Glass D. N. Juvenile rheumatoid arthritis and HLA: report of the Park City III workshop. J. Rheumatol. 1992; 33 (Suppl.): 70–74.

21. Thompson S. D. et al. A genome-wide scan for juvenile rheumatoid arthritis in affected sibpair families provides evidence of linkage. Arthritis Rheum. 2004; 50 (9): 2920–2930.

22. Fishman D. et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J. Clin. Invest. 1998; 102: 1369–1376.

23. Ogilvie E. M. et al. The -174G allele of the interleukin-6 gene confers susceptibility to systemic arthritis in children: a multicenter study using simplex and multiplex juvenile idiopathic arthritis families. Arthritis Rheum. 2003; 48: 3202–3206.

24. Donn R. P. et al. A novel 5'-flanking region polymorphism of macrophage migration inhibitory factor is associated with systemiconset juvenile idiopathic arthritis. Arthritis Rheum. 2001; 44: 1782–1785.

25. De Benedetti F. et al. Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2003; 48: 1398–1407.

26. Wittkowski H., Frosch M., Wulffraat N. et al. S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum. 2008; 58: 3924–3931.

27. Frosch M., Ahlmann M., Vogl T. et al. The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2009; 60: 883–891.

28. Vogl T., Tenbrock K., Ludwig S. et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat. Med. 2007; 13: 1042–1049.

29. De Benedetti F., Martini A. Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? J. Rheumatol. 1998; 25: 203–207.

30. De Benedetti F., Massa M., Robbioni P. et al. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 1991; 34: 1158–1163.

31. Chai Z., Gatti S., Toniatti C. et al. Interleukin-6 gene expression in the central nervous system is necessary for fever response to lipopolysacharide or IL-1 : a study in IL-6 deficient mice. J. Exp. Med. 1996; 183: 311–316.

32. Prieur A. M., Roux-Lombard P., Dayer J. M. Dynamics of fever and the cytokine network in systemic juvenile arthritis. Rev. Rhum. Engl. Ed. 1996; 63: 163–170.

33. Gabay C., Kushner I. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 1999; 340: 448.

34. Rooney M., David J., Symons J. et al. Inflammatory cytokine responses in juvenile chronic arthritis. Br. J. Rheum. 1995; 34: 454.

35. Kimura H., Ishibashi T., Uchida T. et al. Interleukin 6 is a differentiation factor for human megakaryocytes in vitro. Eur. J. Immunol. 1990; 20: 1927–1931.

36. D'Hondt V., Humblet Y., Guillaume T. et al. Thrombopoietic effects and toxicity of interleukin-6 in patients with ovarian cancer before and after chemotherapy: a multicentric placebo-controlled, randomized phase Ib study. Blood. 1995; 85: 2347–2353.

37. Weiss G., Goodnough L. T. Anemia of chronic disease. N. Engl. J. Med. 2005; 352: 1011–1023.

38. Nemeth E., Rivera S., Gabayan V. et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Invest. 2004; 113: 1271–1276.

39. Cazzola M., Ponchio L., De B. F. et al. Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. Blood. 1996; 87: 4824–4830.

40. Hinze C. H., Fall N., Thornton S. et al. Immature cell populations and an erythropoiesis gene expression signature in systemic juvenile idiopathic arthritis: Implications for pathogenesis. Arthritis. Res. Ther. 2010; 12: R123.

41. Guerne P. A., Zuraw B. L., Vaughan J. H. et al. Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis. J. Clin. Invest. 1989; 83: 585–592.

42. De Benedetti F., Pignatti P., Gerloni et al. Differences in synovial fluid cytokine levels between juvenile and adult rheumatoid arthritis. J. Rheumatol. 1997; 24: 1403–1409.

43. Eberhardt B. A., Laxer R. M., Andersson U. et al. Local synthesis of both macrophage and T cell cytokines by synovial cells from children with Juvenile rheumatoid arthritis. Clin. Exp. Immunol. 1994; 96: 260–266.

44. Romano M., Sironi M., Toniatti C. et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity. 1997; 6: 315–325.

45. Alonzi T., Fattori E., Lazzaro D. et al. Interleukin 6 is required for the development of collagen-induced arthritis. J. Exp Med. 1998; 187 (4): 461–468.

46. Tamura T., Udagawa N., Takahashi N. et al. Soluble interleukin- 6 receptor triggers osteoclast formation by interleukin 6. Proc. Natl. Acad. Sci. USA. 1993; 90: 11924–11928.

47. Legendre F., Dudhia J., Pujol J. P., Bogdanowicz P. J. AK/STAT but not ERK1/ERK2 pathway mediates interleukin (IL)-6/soluble IL-6R down-regulation of Type II collagen, aggrecan core, and link protein transcription in articular chondrocytes. Association with a downregulation of SOX9 expression. J. Biol. Chem. 2003; 278: 2903.

48. Ansell B. M., Bywaters E. G. Growth in Still’s disease. Ann. Rheum. Dis. 1956; 15: 295–319.

49. De Benedetti F., Alonzi T., Moretta A. et al. Interleukin-6 causes growth impairment in transgenic mice through a decrease in Insulinlike growth factor 1: a model of stunted growth in children with chronic inflammation. J. Clin. Invest. 1997; 99: 643–650.

50. De Benedetti F., Rucci N., Del Fattore A. et al. Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. Arthritis&Rheum. 2006; 54: 3551.

51. Yokota S., Imagawa T., Mori M. et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008; 371: 998–1006.

52. Yutaka I., Ozawa R., Imagawa T. et al. Radiographic improvement of damaged large joints in children with systemic juvenile idiopathic arthritis following tocilizumab. Ann. Rheum Dis. 2011; Epub ahead of print.

53. Verbsky J. W., White A. J. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J. Rheumatol. 2004; 31: 2071–2075.

54. Irigoyen P. I., Olson J., Hom C., Ilowite N. T. Treatment of systemic onset juvenile rheumatoid arthritis with anakinra. Arthritis Rheum. 2004; 50 (Suppl): S437.

55. Henrickson M. Efficacy of anakinra in refractory systemic arthritis. Arthritis Rheum. 2004; 50 (Suppl): S438.

56. Prieur A. M. et al. Specific interleukin-1 inhibitor in serum and urine of children with systemic juvenile chronic arthritis. Lancet. 1987; 2 (8570): 1240–1242.

57. Gattorno M., Piccini A., Lasiglie D. et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2008; 58: 1505–1515.

58. Quartier P., Allantaz F., Cimaz R. et al. A multicenter, randomized, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS). Ann Rheum Dis. 2011; 70: 747–754.

59. Nigrovic P., Mannion M., Prince F. H. et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011; 63: 545–555.